iShares Biotechnology ETF
414 hedge funds and large institutions have $3.86B invested in iShares Biotechnology ETF in 2016 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 130 increasing their positions, 143 reducing their positions, and 75 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 143
4% less funds holding
Funds holding: 431 → 414 (-17)
11% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 75
32% less call options, than puts
Call options by funds: $608M | Put options by funds: $901M
34% less funds holding in top 10
Funds holding in top 10: 32 → 21 (-11)
36% less capital invested
Capital invested by funds: $6B → $3.86B (-$2.14B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$136M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$113M |
| 3 |
Jane Street
New York
|
+$67.1M |
| 4 |
Two Sigma Advisers
New York
|
+$52.8M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$485M |
| 2 |
JP Morgan Chase
New York
|
-$182M |
| 3 |
Goldman Sachs
New York
|
-$120M |
| 4 |
Morgan Stanley
New York
|
-$111M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$95M |
IBB Hedge Fund Activity: Q1 2016 in Review
414 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2016, worth a combined $3.86B — down 36% from $6B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of IBB and 67 opened new positions — a net loss of 8 holders — while 143 trimmed existing stakes and 130 added.
The largest buyer was Citigroup, adding an estimated $136M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $485M.
- 414 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2016, down from 431 in Q4 2015.
- Funds reported $3.86B of iShares Biotechnology ETF stock for Q1 2016, down 36% quarter-over-quarter.
- 67 funds opened new iShares Biotechnology ETF positions in Q1 2016 and 75 closed out, a net change of -8 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2016 was Citigroup, an estimated $136M added.
- The largest iShares Biotechnology ETF seller in Q1 2016 was BNP Paribas Financial Markets, an estimated $485M sold.
Based on aggregated 13F filings for Q1 2016.